Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1958 1
1962 1
1964 3
1965 1
1967 2
1968 1
1969 3
1970 2
1971 3
1972 2
1973 1
1974 3
1975 17
1976 15
1977 18
1978 17
1979 20
1980 27
1981 12
1982 19
1983 39
1984 37
1985 43
1986 51
1987 80
1988 55
1989 92
1990 88
1991 114
1992 117
1993 113
1994 153
1995 164
1996 136
1997 168
1998 153
1999 141
2000 179
2001 150
2002 145
2003 191
2004 194
2005 193
2006 217
2007 240
2008 212
2009 239
2010 269
2011 293
2012 295
2013 297
2014 292
2015 270
2016 276
2017 239
2018 251
2019 250
2020 284
2021 303
2022 408
2023 417
2024 140

Text availability

Article attribute

Article type

Publication date

Search Results

7,378 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Medulloepithelioma Not Otherwise Specified"
Page 1
FDA Approval Summary: Belzutifan for von Hippel-Lindau Disease-Associated Tumors.
Fallah J, Brave MH, Weinstock C, Mehta GU, Bradford D, Gittleman H, Bloomquist EW, Charlab R, Hamed SS, Miller CP, Dorff SE, Chambers WA, Mixter BD, Dinin J, Pierce WF, Ricks TK, Tang S, Donoghue M, Pazdur R, Amiri-Kordestani L, Ibrahim A, Beaver JA. Fallah J, et al. Clin Cancer Res. 2022 Nov 14;28(22):4843-4848. doi: 10.1158/1078-0432.CCR-22-1054. Clin Cancer Res. 2022. PMID: 35727604 Free PMC article.
On August 13, 2021, the FDA approved belzutifan (WELIREG, Merck), a first-in-class hypoxia-inducible factor (HIF) inhibitor for adult patients with von Hippel-Lindau (VHL) disease who require therapy for associated renal cell carcinoma (RCC), central nervous system (CNS) hemangio …
On August 13, 2021, the FDA approved belzutifan (WELIREG, Merck), a first-in-class hypoxia-inducible factor (HIF) inhibitor for adult patien …
Temozolomide with irinotecan versus temozolomide, irinotecan plus bevacizumab for recurrent medulloblastoma of childhood: Report of a COG randomized Phase II screening trial.
Levy AS, Krailo M, Chi S, Villaluna D, Springer L, Williams-Hughes C, Fouladi M, Gajjar A. Levy AS, et al. Pediatr Blood Cancer. 2021 Aug;68(8):e29031. doi: 10.1002/pbc.29031. Epub 2021 Apr 12. Pediatr Blood Cancer. 2021. PMID: 33844469 Free PMC article. Clinical Trial.
This study compared the overall survival (OS) of patients receiving temozolomide (TMZ) and irinotecan with that of patients receiving TMZ, irinotecan, and bevacizumab for recurrent MB/central nervous system (CNS) primitive neuroectodermal tumor (PNET). METHODS: Pati …
This study compared the overall survival (OS) of patients receiving temozolomide (TMZ) and irinotecan with that of patients receiving TMZ, i …
Metabolism of pancreatic neuroendocrine tumors: what can omics tell us?
Jannin A, Dessein AF, Do Cao C, Vantyghem MC, Chevalier B, Van Seuningen I, Jonckheere N, Coppin L. Jannin A, et al. Front Endocrinol (Lausanne). 2023 Oct 16;14:1248575. doi: 10.3389/fendo.2023.1248575. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 37908747 Free PMC article. Review.
INTRODUCTION: Reprogramming of cellular metabolism is now a hallmark of tumorigenesis. In recent years, research on pancreatic neuroendocrine tumors (pNETs) has focused on genetic and epigenetic modifications and related signaling pathways, but few studies have been devote …
INTRODUCTION: Reprogramming of cellular metabolism is now a hallmark of tumorigenesis. In recent years, research on pancreatic neuroendocrin …
Renal Ewing tumors.
Zöllner S, Dirksen U, Jürgens H, Ranft A. Zöllner S, et al. Ann Oncol. 2013 Sep;24(9):2455-61. doi: 10.1093/annonc/mdt215. Epub 2013 Jun 11. Ann Oncol. 2013. PMID: 23761687 Free article.
BACKGROUND: Renal Ewing's sarcoma/primitive neuroectodermal tumor (ES/PNET) is extremely rare. Clinical symptoms are nonspecific presenting abdominal pain, palpable mass, and hematuria. ...Twenty-four patients were identified and analyzed. The median time of obse …
BACKGROUND: Renal Ewing's sarcoma/primitive neuroectodermal tumor (ES/PNET) is extremely rare. Clinical symptoms are nonspecif …
Management of small, asymptomatic, non-functioning pancreatic neuroendocrine tumours: follow-up, ablation, or surgery?
Dąbkowski K, Starzyńska T. Dąbkowski K, et al. Endokrynol Pol. 2023;74(1):25-30. doi: 10.5603/EP.a2022.0080. Epub 2022 Dec 15. Endokrynol Pol. 2023. PMID: 36519652 Free article. Review.
However, some studies show metastatic potential of these tumours, fuelling an ongoing debate in the literature regarding their management. Making the decision to observe or perform surgery is thus not an easy task. New, promising therapeutic methods involving ablation unde …
However, some studies show metastatic potential of these tumours, fuelling an ongoing debate in the literature regarding their management. M …
Two machine learning-based nomogram to predict risk and prognostic factors for liver metastasis from pancreatic neuroendocrine tumors: a multicenter study.
Li J, Huang L, Liao C, Liu G, Tian Y, Chen S. Li J, et al. BMC Cancer. 2023 Jun 9;23(1):529. doi: 10.1186/s12885-023-10893-4. BMC Cancer. 2023. PMID: 37296397 Free PMC article.
BACKGROUND: Pancreatic neuroendocrine tumors (PNETs) are one of the most common endocrine tumors, and liver metastasis (LMs) are the most common location of metastasis from PNETS; However, there is no valid nomogram to predict the diagnosis and prognosis of l …
BACKGROUND: Pancreatic neuroendocrine tumors (PNETs) are one of the most common endocrine tumors, and liver metastasis (LMs) a …
Prognostic factors of sarcomas occurring in bone and joint: A SEER based study.
Zhou H, He S, Zhang D, Wang J, Yang X, Jiao J, Xu W, Yang J, Xiao J. Zhou H, et al. Medicine (Baltimore). 2023 Oct 27;102(43):e34231. doi: 10.1097/MD.0000000000034231. Medicine (Baltimore). 2023. PMID: 37904412 Free PMC article.
The calibration curve for the probability of survival showed good agreement between prediction by the nomogram and actual observation. The C-index of the nomogram for survival prediction was 0.814. Patients who received chemotherapy had a significantly decrea …
The calibration curve for the probability of survival showed good agreement between prediction by the nomogram and actual observat …
Prognostic value of CT characteristics in GEP-NET: A systematic review.
van der Velden DL, Staal FCR, Aalbersberg EA, Castagnoli F, Wilthagen E, Beets-Tan RGH. van der Velden DL, et al. Crit Rev Oncol Hematol. 2022 Jul;175:103713. doi: 10.1016/j.critrevonc.2022.103713. Epub 2022 May 20. Crit Rev Oncol Hematol. 2022. PMID: 35598829 Review.
Larger tumor size, hypo-enhancement, irregular shape and ill-defined margins, presence of locally invasive growth, lymphadenopathy and metastases were predictors of poorer prognosis according to 65-89% of the available studies. ...Therefore, we feel that the before-mention …
Larger tumor size, hypo-enhancement, irregular shape and ill-defined margins, presence of locally invasive growth, lymphadenopathy and metas …
TUMORS OF THE NONPIGMENTED EPITHELIUM OF THE CILIARY BODY: The Lorenz E. Zimmerman Tribute Lecture.
Shields JA, Eagle RC Jr, Ferguson K, Shields CL. Shields JA, et al. Retina. 2015 May;35(5):957-65. doi: 10.1097/IAE.0000000000000445. Retina. 2015. PMID: 25545484 Review.
Lorenz Zimmerman delivered the Norman McAlister Gregg Lecture entitled "The remarkable polymorphism of tumors of the ciliary epithelium." Therein, he proposed a classification of these tumors that included congenital lesions (mainly medulloepithelioma) and ac …
Lorenz Zimmerman delivered the Norman McAlister Gregg Lecture entitled "The remarkable polymorphism of tumors of the ciliary epitheli …
Multiple Endocrine Neoplasia Type 1 Syndrome Pancreatic Neuroendocrine Tumor Genotype/Phenotype: Is There Any Advance on Predicting or Preventing?
Ramamoorthy B, Nilubol N. Ramamoorthy B, et al. Surg Oncol Clin N Am. 2023 Apr;32(2):315-325. doi: 10.1016/j.soc.2022.10.008. Surg Oncol Clin N Am. 2023. PMID: 36925188 Free PMC article. Review.
Multiple endocrine neoplasia type 1 syndrome (MEN1) is a disease caused by mutations in the MEN1 tumor suppressor gene leading to hyperparathyroidism, pituitary adenomas, and entero-pancreatic neuroendocrine tumors. Pancreatic neuroendocrine tumors (PNETs) are a maj …
Multiple endocrine neoplasia type 1 syndrome (MEN1) is a disease caused by mutations in the MEN1 tumor suppressor gene leading to hyperparat …
7,378 results